Table 2.

Comparison of biomarker changes from baseline to C2D1 in response to TRC105 monotherapy, BEV monotherapy, and the combination of both TRC105 and BEV

TRC105 monoBEV monoTRC+BEV
Regimen markerDirectionP valueDirectionP valueDirectionP value
BEV-specificPlGF0.0851<0.0001<0.0001
TSP-20.03180.00010.099
TRC-specificEndoglin<0.0001n/a<0.0001
E-Cadherin0.0203<0.00010.103
E-Selectin0.0081<0.0001<0.0001
vWF0.02190.09180.002
Combo-similarAng-20.0028<0.0001<0.0001
IL60.0255n.s.0.006
VCAM-10.0755<0.0001<0.0001
Combo-opposingTGFβ10.14850.0143<0.001
PDGF-AA0.01470.00860.002
PDGF-BB0.00510.0030.007
PAI-1 active0.14910.0270.003
PAI-1 total0.01150.00020.005
Combo-neutralizingIGFBP-30.00250.1035n.s.
VEGF-A0.10110.1392n.s.
VEGF-D0.00670.0011n.s.
  • NOTE: Down-pointed arrows indicate an overall decrease of the marker after one cycle of treatment, whereas up-pointed arrows indicate an increase of the marker after one cycle of treatment. P values less than 0.05 are considered statistically significant, whereas P values between 0.05 and 0.15 represent potential trends.

  • Abbreviations: n/a, not available; n.s., not significant.